Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd (TLSA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
tlsa · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Tiziana Life Sciences LtdYou TLSA | $72M | N/A | — | -$0.19 |
 Anebulo Pharmaceuticals, Inc. ANEB | $15M | N/A | — | -$0.25 |
 Coya Therapeutics, Inc. COYA | $84M | N/A | — | -$1.27 |
 Estrella Immunopharma, Inc. ESLA | $48M | N/A | — | -$0.35 |
 eXoZymes, Inc. EXOZ | $71M | N/A | — | -$1.09 |
 Immix Biopharma, Inc. IMMX | $435M | N/A | — | -$0.89 |
 MacroGenics, Inc. MGNX | $257M | N/A | — | -$1.18 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Tiziana Life Sciences Ltd (TLSA) measures how much investors pay for each dollar of the company's trailing earnings. TLSA's current PE ratio of N/A is calculated by dividing its stock price of $1.22 by its TTM earnings per share of -$0.19.
Frequently asked questions
TLSA pe ratio · 6 questionsTLSA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.22 and TTM EPS of -$0.19. Data sourced from Financial Modeling Prep via TLSA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Tiziana Life Sciences Ltd SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09